Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Maximum Tolerated Dose. Found 18 abstracts

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-92.
Kantarjian HM, Roboz GJ, Kropf PL, Yee KW, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Oct;18(10):1317-26.   PMCID: PMC5925750
Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Oct;23(19):5703-10.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-501.
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs. 2015 Aug;26(7):785-92.   PMCID: 4484664
Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90.   PMCID: PMC4643003
Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014 Sep 15;20(18):4747-57.   PMCID: 4377301
Plimack ER, Desai JR, Issa JP, Jelinek J, Sharma P, Vence LM, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu WJ. A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: Impact on DNA methylation and lymphocyte populations. Investigational New Drugs. 2014 Oct;32(5):969-75.   PMCID: 4171200
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.   PMCID: Pmc4045341
Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54.   PMCID: PMC3026871
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008 Nov;3(11):1286-92.
Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Annals of Surgical Oncology 13 (2): 150-158 Feb 2006. 2006 Feb;13(2):150-8.
Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Current treatment options in oncology. 2005 Mar;6(2):115-20.
Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ. Phase I and pharmacokinetic study of once daily oral administration of s-1 in patients with advanced cancer. Clin Cancer Res. 2002 Jul;8(7):2116-22.
Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller D, Algazy K, Giantonio B, Alila H, O'Dwyer PJ. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res. 2002 Oct;8(10):3100-4.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Maximum Tolerated Dose

Maximum Tolerated Dose Aged Female Male Middle Aged drug therapy adverse effects administration & dosage Adult Drug Dose-Response Relationship pathology Drug Administration Schedule therapeutic use 80 and over Aged Neoplasms Treatment Outcome pharmacokinetics effects Antineoplastic Agents adverse antagonists & inhibitors mortality Neoplasm Staging Prognosis metabolism chemically induced analogs & derivatives Monoclonal Antibodies Survival Analysis Antineoplastic Combined Chemotherapy Protocols Intravenous Infusions immunology Patient Safety analogs & Local Neoplasm Recurrence derivatives Disease-Free Survival Neoplasm Invasiveness Human Pyrimidines Antineoplastic Antimetabolites statistics & numerical data Multiple Myeloma Kaplan-Meier Estimate Deoxycytidine Monoclonal Antibodies-Humanized Comparative Study pharmacology diagnosis Oral Administration Non-US Gov't Support methods Epidermal Growth Factor Receptor Squamous Cell Carcinoma Prospective Studies genetics Half-Life Azacitidine therapy Survival Rate Risk Assessment blood Neoplasm Drug Resistance Cisplatin Middle Age T-Lymphocyte Subsets Safety Sarcoma Young Adult Paclitaxel Disorders of Excessive Somnolence Oligopeptides drug effects Biological Availability Myeloid Leukemia-Acute Radiotherapy Dosage ErbB-2 Receptor Adenocarcinoma US Gov't Support-PHS Radiotherapy Sulindac Quinazolines 0 (Piperazines) Recombinant Proteins Drug Combinations Internationality Bispecific Antibodies United States Retreatment Protein Kinase Inhibitors Neutropenia Insulin-Like Growth Factor II Tegafur Benzazepines pc [Prevention & Control] Methylphenidate administration & Biomarkers Carboplatin pk [Pharmacokinetics] Central Nervous System Stimulants Interferon-alpha inhibitors Alanine Transaminase Molecular Targeted Therapy Benzhydryl Compounds Academic Medical Centers Single-Blind Method Epothilones 0 (Pyrimidines) Histone Deacetylases secondary Aspartate Aminotransferases Recurrence Pyridines Confidence Intervals Female Genital Neoplasms Tissue Distribution tu [Therapeutic Use] Drug Monitoring Granulocyte-Macrophage Colony-Stimulating Factor Receptors Thalidomide Time Factors Cyclopentanes pa [Pathology] Polyethylene Glycols Oxonic Acid Pneumonia dt [Drug Therapy] Protein-Serine-Threonine Kinases Ubiquitins Neoplasm Metastasis Uterine Neoplasms Bronchiolo-Alveolar Adenocarcinoma Head and Neck Neoplasms Neoadjuvant Therapy Insulin-Like Growth Factor I Cohort Studies Dexamethasone Ovarian Neoplasms Leukocyte Count Drug-Related Side Effects and Adverse Reactions Bone Neoplasms Urologic Neoplasms Macrophage Colony-Stimulating Factor Lymphoma antagonists & Lung Neoplasms Folic Acid 152459-95-5 (imatinib)
Last updated on Monday, August 03, 2020